<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790097</url>
  </required_header>
  <id_info>
    <org_study_id>FET-PET SIB Boost</org_study_id>
    <nct_id>NCT04790097</nct_id>
  </id_info>
  <brief_title>FET-PET Directed Simultaneous In-field Boost for Primary GBM</brief_title>
  <acronym>dualFETboost</acronym>
  <official_title>Safety and Preliminary Efficacy of Hipofractionated Irradiation Based on Dual FET-PET in Patients With Primary Glioblastoma Multiforme With Concomitant Temozolomide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Franciszek Lukaszczyk Memorial Oncology Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prof. Franciszek Lukaszczyk Memorial Oncology Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of anatomical MRI examination with functional examination of tissue metabolic&#xD;
      activity such as FET-PET (PET using the radiotracer - 18F-fluoro-ethyl-tyrosine) is a&#xD;
      valuable tool to determine the actual tumor infiltration. The FET-PET examination can be&#xD;
      performed using the dual-time point aqusition of FET for exact treatment planning. It has&#xD;
      also been proven that using the dual FET-PET method, it is possible to obtain a precise image&#xD;
      of the glioblastoma infiltration corresponding to the location and shape of the recurrence,&#xD;
      and the tumor volumes in dual FET-PET are significantly larger than in MRI. Moreover, tumor&#xD;
      defined in dual FET-PET is different than that of the tumor defined in single FET-PET&#xD;
      acquisition.&#xD;
&#xD;
      In the DualFETboosT trial we plan to assess the safety and preliminary efficacy of&#xD;
      hypofractionated irraditon using simultaneous in-field boost directed on dual FET-PET based&#xD;
      tumor volumes for treatment of primary glioblastoma multiforme with concomitant temozolomide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the case of the treatment of glioblastoma multiforme, as a standard, radiotherapy lasts 6&#xD;
      weeks, and the extension of treatment may adversely affect the tumor cells death, the&#xD;
      patient's well-being and treatment costs (prolonged hospitalization). In turn, escalating the&#xD;
      dose may increase the toxicity of radiation therapy by increasing DNA damage in healthy brain&#xD;
      tissue. Using of dual FET-PET images for treatment planning allow to reduce volumes of&#xD;
      healthy tissue irradiated. Dose-intensification proposed in the study using simultaneous&#xD;
      in-field boost allows the dose escalation without increasing the overall treatment time. All&#xD;
      patient will be treated with moderately hypofractionated radiotherapy (2.6 Gy per fraction)&#xD;
      directed on PET positive volumes and conventional fractionation (60Gy in 30 fractions) on&#xD;
      tumor margin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2017</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>assessed up to 24 months</time_frame>
    <description>From date of surgery until the date of death from any cause, percent of patient that are alive 1 and 2 years after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 24 months</time_frame>
    <description>from the date of surgery until progression of the disease or the date of death from any cause assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>up to 9 months</time_frame>
    <description>according to Rano criteria; from the end of radiation therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of treatment failure</measure>
    <time_frame>up to 24 months</time_frame>
    <description>from the end of radiation therapy up to progression until progression of the disease or the date of death from any cause; according to irradiation field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation necrosis</measure>
    <time_frame>assessed up to 24 months</time_frame>
    <description>from the end of radiation therapy up to progression until progression of the disease or the date of death from any cause; histopathological diagnosis of radiation necrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 6 months</time_frame>
    <description>from the end of radiation therapy up to progression until progression of the disease or the date of death from any cause; CTCAE grade 3 or higher</description>
  </secondary_outcome>
  <other_outcome>
    <measure>FET predictive value</measure>
    <time_frame>up to 24 months</time_frame>
    <description>From date of surgery until the date of death from any cause, Correlation between FET uptake and survival</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Simultaneous In-Field Boost on FET-PET positive target volumes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Moderately Hypofractionated Radiotherapy using Simultaneous In-Field Boost</intervention_name>
    <description>78Gy in 30 fractions on FET-PET based target volumes;&#xD;
60Gy in 30 fractions on 2cm margin from MRI based target volumes;&#xD;
all patients will be treated with concomitant and adjuvant temozolomide</description>
    <arm_group_label>Simultaneous In-Field Boost on FET-PET positive target volumes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological confirmation of glioblastoma (WHO grade IV)&#xD;
&#xD;
          -  Age between 18-75 years of age&#xD;
&#xD;
          -  General condition according to the Zubrod scale 0 or 2&#xD;
&#xD;
          -  The results of the blood counts are normal&#xD;
&#xD;
          -  Liver enzyme parameters normal&#xD;
&#xD;
          -  The results of the parameters of the patient's functions are normal&#xD;
&#xD;
          -  Informed consent to participate in the category&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coexistence of another cancer&#xD;
&#xD;
          -  The location of the tumor in the area of the brain stem or cerebellum&#xD;
&#xD;
          -  Prior brain radiation therapy&#xD;
&#xD;
          -  No uptake visible in the FET-PET imaging&#xD;
&#xD;
          -  Contraindications for MRI&#xD;
&#xD;
          -  Contraindications to radiotherapy or chemotherapy&#xD;
&#xD;
          -  Pregnancy, lack of consent to the use of protection against pregnancy, puerperium&#xD;
&#xD;
          -  Alcohol addiction&#xD;
&#xD;
          -  Mental illness&#xD;
&#xD;
          -  Claustrophobia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Franciszek Lukaszczyk Oncology Center</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prof. Franciszek Lukaszczyk Memorial Oncology Center</investigator_affiliation>
    <investigator_full_name>Maciej Harat</investigator_full_name>
    <investigator_title>M.D Ph.D.</investigator_title>
  </responsible_party>
  <keyword>FET-PET</keyword>
  <keyword>Boost</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Dose-intesification</keyword>
  <keyword>Dose-escalation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

